INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo TYPHOID VACCINE

TYPHOID VACCINE
Typhoid/Vac

PROPRIETARY NAME:
TYPHOID VACCINE

DESCRIPTIVE NAME:
A Bacterial
Typhoid Prophylactic Vaccine

REGISTRATION NUMBER:
T530 (Act 101/1965)

PHARMACOLOGICAL CLASSIFICATION:
A30.1 Antigens

SCHEDULING STATUS:
S2

COMPOSITION:
A suspension in Saline Solution containing 1 000 million of heat-killed Salmonella typhi per 0,5 mL and 0,5% Phenol as preservative.

IDENTIFICATION:
A pale milky translucent suspension with a slight odour due to the preservative.

PHARMACOLOGICAL ACTION:
Induces in the recipient a specific active immunity to Typhoid Fever.

INDICATIONS:
For active immunisation against Typhoid Fever.

CONTRA-INDICATIONS:
Not recommended for patients with acute infections or chronic illness, or for children less than 1 year old. Should be used with great caution if there has been a history of allergy to previous vaccination.

DOSAGE AND DIRECTIONS FOR USE:
For primary immunisation of adults, 2 doses, usually of 0,5 mL, are given by deep subcutaneous injection, preferably 4 weeks apart; a reinforcing dose may be given 6 months after the second dose. Children from 1 to 5 years are given half the adult dose (0,25 mL). A booster dose may be given after two years, but thereafter, only when the subject is at risk. Sterilise the rubber closure with tincture of iodine and shake vial vigorously before use.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Enquiry regarding previous hypersensitivity should precede the administration of a vaccine, and measures to treat reactions should be immediately available. Anaphylactic reactions, which are rare, should be treated with adrenaline, possibly in association with antihistamine and corticosteroid therapy.

Reactions following administration may include anorexia, fever, vomiting, and malaise. May cause transient local and general reactions for which symptomatic treatment should be given. Local reactions are more likely to occur after reinforcing or booster doses.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
No known symptoms.

PRESENTATION:
Single dose ampoules containing 0,5 mL.
Multidose 10 mL vials (20 doses) packed singly.
Multidose 10 mL vials packed 10 x 10 mL.

STORAGE INSTRUCTIONS:
Store at 2° C to 10° C. DO NOT FREEZE. Protect from light.

NAME AND BUSINESS ADDRESS OF APPLICANT:
The South African Institute for Medical Research.
Rietfontein, Edenvale, Transvaal.
P.O. Box 28999, Sandringham, 2131

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
February 1990

121-1192

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996,1997,1998